专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

111. 发明专利

AP2218A Azithromycin dosage forms with reduced side effects 未知
公开(公告)号：AP2218A
公开(公告)日：2011-04-20
申请号：AP2004003145
申请日：2004-05-14
申请人： PFIZER PROD INC
发明人： HAGEN TIMOTHY ARTHUR , HERBIG SCOTT MAX , LO JULIAN BELKNAP , THOMBRE AVINASH GOVIND , APPEL LEAH ELIZABETH , CREW MARSHALL DAVID , FRIESEN DWAYNE THOMAS , LYON DAVID KEITH , MCCRAY SCOTT BALDWIN , WEST JAMES BLAIR
IPC分类号： A61K9/00 , A61K9/16 , A61K38/00 , C07H17/00
摘要： An oral dosage form comprising azithromycin and an effective amount of an alkalizing agent. Preferably, said oral dosage form comprises an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule. Additionally disclosed is an oral suspension comprising azithromycin, an effective amount of an alkalizing agent and a vehicle. Preferably, the azithromycin is in multiparticulate form wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer. Also disclosed is a method for reducing gastrointestinal side effects, associated with administering azithromycin to a mammal, comprising contiguously administering azithromycin and an effective amount of alkalizing agent to said mammal wherein the frequency of gastrointestinal side effects is lower than that experienced by administering an equal dose of azithromycin without said alkalizing agent. Further disclosed is a method of treating a bacterial or protozoal infection in a mammal in need thereof comprising contiguously administering to said mammal a single dose of an oral dosage form wherein said oral dosage form comprises azithromycin and an effective amount of an alkalizing agent. Additionally disclosed are azithromycin multiparticulates comprising azithromycin, a surfactant; and a pharmaceutically acceptable carrier.

113. 发明专利

AT433318T 未知
公开(公告)号：AT433318T
公开(公告)日：2009-06-15
申请号：AT00300572
申请日：2000-01-26
申请人： PFIZER PROD INC
发明人： APPEL LEAH ELIZABETH , CURATOLO WILLIAM JOHN , HERBIG SCOTT MAX , NIGHTINGALE JAMES ALAN SCHRIVER , THOMBRE AVINASH GOVIND
IPC分类号： A61K9/22 , A61K9/26 , A61K9/00 , A61K9/14 , A61K9/16 , A61K9/50 , A61K9/52 , A61K31/135 , A61K31/137 , A61K31/17 , A61K31/36 , A61K31/404 , A61K31/44 , A61K31/497 , A61K31/505 , A61K31/517 , A61K31/522 , A61K47/32 , A61K47/34 , A61K47/38

114. 发明专利

NZ535464A Azithromycin dosage forms with reduced side effects 未知
公开(公告)号：NZ535464A
公开(公告)日：2009-03-31
申请号：NZ53546404
申请日：2004-05-14
申请人： PFIZER PROD INC
发明人： HAGEN TIMOTHY ARTHUR , HERBIG SCOTT MAX , LO JULIAN BELKNAP , THOMBRE AVINASH GOVIND , APPEL LEAH ELIZABETH , CREW MARSHALL DAVID , FRIESEN DWAYNE THOMAS , LYON DAVID KEITH , WEST JAMES BLAIR , MCCRAY SCOTT BALDWIN
IPC分类号： C07H17/00 , A61K9/00 , A61K9/16 , A61K9/20 , A61K31/7052 , A61K47/02 , A61K47/14 , A61K47/18 , A61K47/44 , A61P31/04
摘要： Disclosed is an oral dosage form comprising: a) an effective amount of an alkalizing agent; and b) multiparticulates comprising i) azithromycin; ii) a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate; and iii) a poloxamer.

116. 发明专利

EA010110B1 ДОЗИРОВАННЫЕ ФОРМЫ АЗИТРОМИЦИНА С ПОНИЖЕННЫМИ ПОБОЧНЫМИ ЭФФЕКТАМИ 未知
公开(公告)号：EA010110B1
公开(公告)日：2008-06-30
申请号：EA200401216
申请日：2004-05-14
申请人： PFIZER PROD INC
发明人： HAGEN TIMOTHY ARTHUR , HERBIG SCOTT MAX , LO JULIAN BELKNAP , THOMBRE AVINACH GOVIND , APPEL LEAH ELIZABETH , CREW MARSHALL DAVID , FIESEN DWAYNE THOMAS , LYON DAVID KEITH , MCCRAY SCOTT BALDWIN , WEST JAMES BLAIR
IPC分类号： A61K9/16 , C07H17/00 , A61K9/00 , A61K9/20 , A61K31/7052 , A61K47/02 , A61K47/14 , A61K47/18 , A61K47/44 , A61P31/00 , A61P31/04
摘要： Настоящееизобретениераскрываетпероральнуюдозированнуюформу, включающуюазитромицини эффективноеколичествоподщелачивающегоагента. Предпочтительноуказаннаяпероральнаядозированнаяформавключаетэффективноеколичествоподщелачивающегоагентаи мультичастицыазитромицина, гдеуказанныемультичастицывключаютазитромицин, смесьглицерилмонобегената, глицерилдибегенатаи глицерилтрибегенатаи полоксамер. Обычнопероральнаядозированнаяформавключаетлюбыеподходящиеформыдозировкидляпероральноговведения, такиекакпорошокдляпероральнойсуспензии, сединичнойдозой, пакетилисаше, таблеткаиликапсула. Дополнительнораскрытапероральнаясуспензия, включающаяазитромицин, эффективноеколичествоподщелачивающегоагентаи носитель. Предпочтительноазитромициннаходитсяв формемультичастиц, гдеуказанныемультичастицывключаютазитромицин, смесьглицерилмонобегената, глицерилдибегенатаи глицерилтрибегенатаи полоксамер. Такжераскрытспособсниженияжелудочно-кишечныхпобочныхэффектов, связанныхс введениемазитромицинамлекопитающему, включающийсопутствующеевведениеазитромицинаи эффективногоколичестваподщелачивающегоагентауказанномумлекопитающему, прикоторомчастотажелудочно-кишечныхпобочныхэффектовсниженапосравнениюс традиционнойвводимойравнойдозойазитромицинабезуказанногоподщелачивающегоагента. Дополнительнораскрытспособлечениябактериальнойилипротозойнойинфекцииу нуждающегосяв этоммлекопитающего, включающийсопутствующеевведениеуказанномумлекопитающемуоднократнойдозыпероральнойдозированнойформы, где

117. 发明专利

BRPI0514416A 未知
公开(公告)号：BRPI0514416A
公开(公告)日：2008-06-10
申请号：BRPI0514416
申请日：2005-08-19
申请人： PFIZER PROD INC
发明人： APPEL LEAH ELIZABETH , FRIESEN DWAYNE THOMAS , HERBIG SCOTT MAX , THOMBRE AVINASH GOVIND
IPC分类号： A61K9/20 , A61K9/50 , A61K31/496

118. 发明专利

NZ539915A Controlled-release of an active substance into a high fat environment 未知
公开(公告)号：NZ539915A
公开(公告)日：2007-09-28
申请号：NZ53991503
申请日：2003-11-28
申请人： PFIZER PROD INC
发明人： CHIDLAW MARK BRIAN , FRIESEN DWAYNE THOMAS , HERBIG SCOTT MAX , NIGHTINGALE JAMES ALAN SCHRIVE , OKSANEN CYNTHIA ANN , WEST JAMES BLAIR
IPC分类号： A61K9/00 , A61K9/20 , A61K9/28 , A61K9/36 , A61K31/137 , A61K31/4985 , A61K31/135 , A61K31/495 , A61K31/00
摘要： Disclosed is a use of a composition comprising an active-substance-containing core and an asymmetric polymeric coating thereon, in the manufacture of a medicament for controlled-release delivery upon administration of said composition to a use environment comprising at least about 0.5 wt% of dietary fat, wherein the polymer used to form said asymmetric polymeric coating comprises cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate, cellulose acetate phthalate, hydroxypropyl methyl cellulose acetate succinate, polymethacrylate, or mixtures or-blends thereof.

119. 发明专利

UA78793C2 ORAL DOSAGE FORM OF AZITROMYCIN WITH DECREASED SIDE EFFECTS 未知
公开(公告)号：UA78793C2
公开(公告)日：2007-04-25
申请号：UA20041210181
申请日：2004-05-14
申请人： PFIZER PROD INC
发明人： HAGEN TIMOTHY ARTHUR , HERBIG SCOTT MAX , LO JULIAN BELKNAP , THOMBRE AVINASH GOVIND , APPEL LEAH ELIZABETH , CREW MARSHALL DAVID , FRIESEN DWAYNE THOMAS , LYON KEITH DAVID , MCCRAY SCOTT BALDWIN , WEST JAMES BLAIR
IPC分类号： A61K9/14 , A61K9/16 , A61K31/704 , A61K38/00 , A61P31/00
摘要： The invention relates to the oral dosage form containing Azitromycin and the effective amount of alkalization agent. Preferably, the said oral dosage form comprises the effective amount of alkalization agent and multiparticles of Azitromycin containing Azitromycin and the mixture of glycerylmonobechenate, glyceryldibechenate, glyceryltribechenate, and poloxamer. Also disclosed are the method for decreasing the gastrointestinal side effects and the method for treating bacterial or protozoal infection in the mammals using the said oral dosage form.

120. 发明专利

BRPI0414082A 未知
公开(公告)号：BRPI0414082A
公开(公告)日：2006-10-24
申请号：BRPI0414082
申请日：2004-08-31
申请人： PFIZER PROD INC
发明人： AHMED IMRAN , BABCOCK WALTER CHRISTIAN , FRIESEN DWAYNE THOMAS , HERBIG SCOTT MAX , SHAMBLIN SHERI LYNN , SHANKER RAVI MYSORE , SMITHEY DANIEL TOD , SUTTON STEVEN C , THOMBRE AVINASH GOVIND , WATERMAN KENNETH C , LYON DAVID KEITH
IPC分类号： A61K9/00 , A61K9/16 , A61K9/20 , A61K9/52 , A61K31/496 , A61K9/22 , A61K9/28
摘要： A sustained release solid oral dosage form for treatment of a psychotic disorder, for example schizophrenia, in a mammal is provided, which oral dosage form comprises ziprasidone in an amount effective in treating said psychotic disorder and a pharmaceutically acceptable carrier.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式